AI & Informatics: Drug discovery and development – industry survey infographic
View Drug Target Review's new infographic on the use of AI and informatics within early therapeutic development here.
List view / Grid view
View Drug Target Review's new infographic on the use of AI and informatics within early therapeutic development here.
Dr Robert Hewitt explores why a shift is required in the way that biosamples are sourced by the drug discovery industry, including smaller biotech companies.
In a new study, researchers at Brigham and Women’s Hospital, US, successfully developed stem cell-derived neuronal profiles from individual patients. Here, Drug Target Review’s Victoria Rees explores the findings and how these new models can help to advance precision and personalised medicine.
Sheraz Gul explores how machine learning and artificial intelligence represent an exciting opportunity for the drug discovery industry, with the potential to develop highly optimised small molecules.
In this original report, find an in-depth analysis of AI and informatics within imaging, synthetic biology, drug screening and drug design. Featured interviews with experts from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
Cell Line Development and cell culture process teams, are you geared up to leverage the vast amount of data generated by high-throughput?
Researchers have developed a 3D “assembloid” that presents a potential entry route of COVID-19 into the brain.
A US team has designed a high-quality, high-speed imaging system that could lead to new understandings of complex tissue specimens.
Drug analysis at the Francis Crick Institute and University of Dundee has revealed 15 potential antivirals that could lead to new COVID-19 treatments.
Dr Robert Hewitt explains why the need of biospecimen brokers to protect their commercially-sensitive information can result in significant issues for industry end-users and the results of their research.
New findings from collaborative research in the United States have identified a promising new treatment avenue for type 2 diabetes patients centring on the activity of the amino acid, GABA.
With a return to the workplace on the horizon for an increasing number of scientists, Richard Goodwin considers how COVID-19 will impact the ways research is conducted. One outcome he posits is the acceleration of the digital transformation that was already occurring in pharmaceutical R&D.
22 April 2021 | By IDBS
Register today for our on-demand upcoming webinar and discover more on about Polar High-Throughput Process Development (HTPD).
An algorithm which continuously processes new data has been developed to allow researchers to access and analyse single-cell sequencing information.
31 March 2021 | By
The new AdvanceBio Sialic Acid profiling and quantitation kit from Agilent provides workflows for the robust and rapid preparation of samples for sialic acid analysis, generating reliable downstream LC-FLD and LC-MS data.